<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02864004</url>
  </required_header>
  <id_info>
    <org_study_id>35RC15_9724_EARLY-PUMP</org_study_id>
    <nct_id>NCT02864004</nct_id>
  </id_info>
  <brief_title>Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)</brief_title>
  <acronym>EARLY-PUMP</acronym>
  <official_title>Apomorphine Pump in Early Stage of Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the use of the apomorphine pump in earlier stages of&#xD;
      Parkinson' Disease (PD), when motor complications have just developed and before patients are&#xD;
      significantly affected in their social and occupational functioning. The investigators&#xD;
      hypothesize that apomorphine pump is superior in terms of positive impact on quality of life&#xD;
      (QoL) to oral medical therapy alone at a relatively early stage of PD, before the appearance&#xD;
      of severe disabling motor complications thus favoring the maintain of patients' social and&#xD;
      occupational status with a significant positive economic impact of the health system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The recruitment period will be 36 months. The duration of the study period will be one year&#xD;
      for each patient due to:&#xD;
&#xD;
        -  adjustments of apomorphine pump parameters and oral medication (3 months interval),&#xD;
&#xD;
        -  motor and psychosocial changes which need time to develop and have an impact on QoL.&#xD;
&#xD;
      At the end of the study period, two additional visits at Months 18 and 24 will be performed&#xD;
      during an long term follow up to collect QoL and costs related data required to&#xD;
      medico-economic analysis.&#xD;
&#xD;
      APOMORPHINE (APO) group:&#xD;
&#xD;
      The apomorphine pump will be installed and adjusted at baseline during a first&#xD;
      hospitalization (10 days). Modifications of the hourly flow of the pump and readjustment&#xD;
      (reduction) of anti-parkinsonian oral medication will be checked and performed at Months 1,&#xD;
      2, 4, 5, 6, 9 during visits and phone calls, and at month 3 during a 3 days hospitalization.&#xD;
      Clinical evaluations will be performed at months 6 and 12.&#xD;
&#xD;
      Control group:&#xD;
&#xD;
      Patients will be treated by optimized medical treatment according to the guidelines of the&#xD;
      European Federation of Neurological Societies. Dose adjustments will be done at Months 3, 6,&#xD;
      9. Clinical evaluations will be performed at months 6 and 12.&#xD;
&#xD;
      In both groups, data for medico-economic evaluation will be collected from patients at&#xD;
      baseline, Months 6, 12, 18 and 24 for Quality Adjusted Life Year (QALYs) and costs related&#xD;
      data from a patient's diary and French Health Insurance database.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the Parkinson's Disease Quality of Life Questionnaire (PDQ39) summary index between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the Patient Global Impression of Change (PGIC)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Neurologist Global Impression of change (CGI-I)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in non-motor aspects of experiences of daily living (MDS-UPDRS I) between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in motor aspects of experiences of daily in &quot;on&quot; and &quot;off&quot; medication (MDS-UPDRS II) between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in motor examination during &quot;on&quot; periods (MDS-UPDRS III) between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in motor complications with MDS-UPDRS IV between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of hours per day in the &quot;best ON&quot; state between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of hours per day in &quot;ON&quot; with dyskinesia between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of hours per day in &quot;OFF&quot; state between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of Sleeping-hours per day between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Score of the Non-Motor Symptoms Scales (NMSS) for PD between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in psychosocial functioning PD (SCOPA-PS) between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in score of depressive symptoms (BDI) between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in occurrence of anxiety (STAI-S) between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain assessed on the Visual Analog Scale (VAS) between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive function between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
    <description>Change in cognitive function assessed by the Neuroscience Parkinson network's (NS-PARK) battery test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in apathy assessed on the Apathy Scale between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in apathy assessed on the short version of Lille Apathy Rating Scale (LARS) between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of dose for treatments assessed by levodopa (L-DOPA) equivalents between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in behavioral symptoms assessed by Ardouin Scale between the baseline assessment and the assessment at 12 months' follow up</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and severity of therapy-related adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin changes assessed by a clinical exam</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full blood count</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness Scale</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental Cost-Effectiveness Ratio (ICER)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>APO group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An apomorphine pump will be installed and adjusted. The target dose corresponds to the patient's individual optimized dose :maximum dose of 10 mg/hour for 16 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be optimally treated with oral dopaminergic therapy to obtain the best medical treatment (BMT) defined as the most efficient single treatment options or their combination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apomorphine</intervention_name>
    <description>Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour</description>
    <arm_group_label>APO group</arm_group_label>
    <other_name>Apokinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Medical Treatment</intervention_name>
    <description>Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged ≤ 65 years,&#xD;
&#xD;
          -  Idiopathic PD (According to British Brain Bank Criteria) without any other known or&#xD;
             suspected cause of Parkinsonism,&#xD;
&#xD;
          -  Hoehn and Yahr stage ≤ 2.5 in the best ON,&#xD;
&#xD;
          -  Disease duration ≥ 4 years,&#xD;
&#xD;
          -  Presence of fluctuations and/or dyskinesias for no more than 3 years,&#xD;
&#xD;
          -  One of the two following forms of impairment :&#xD;
&#xD;
               -  Impairment in activities of daily living (MDS-UPDRS II&gt;6) due to PD-symptoms&#xD;
                  despite medical treatment in the worst condition or,&#xD;
&#xD;
               -  Impairment of social and occupational functioning (measured with SOFAS) due to&#xD;
                  PD-symptoms despite medical treatment (51-80%),&#xD;
&#xD;
          -  PDQ39 completed,&#xD;
&#xD;
          -  Able to understand and remember the component of the study,&#xD;
&#xD;
          -  Written informed consent,&#xD;
&#xD;
          -  Patients covered with social insurance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia (MoCA &lt; 22),&#xD;
&#xD;
          -  Major uncontrolled depression at the time of assessment (BDI &gt; 25) or Bipolar disease,&#xD;
&#xD;
          -  Active hallucinations or history of hallucinations in the past year,&#xD;
&#xD;
          -  Need for nursing care,&#xD;
&#xD;
          -  Previous use of apomorphine pump treatment,&#xD;
&#xD;
          -  History of respiratory depression,&#xD;
&#xD;
          -  History of deep brain stimulation or lesional surgery for PD or intrajejunal L-Dopa,&#xD;
&#xD;
          -  Presence of severe freezing or clinically relevant postural instability leading to&#xD;
             falls during the ON state,&#xD;
&#xD;
          -  Symptomatic clinically relevant and medically uncontrolled orthostatic hypotension,&#xD;
&#xD;
          -  Clinically relevant hepatic dysfunction (total bilirubin &gt;2.0 mg/dL, Alanine Amino&#xD;
             Transferase (ALT) and Aspartate Amino Transferase (AST) &gt;2 times the upper limit of&#xD;
             normal),&#xD;
&#xD;
          -  Clinically relevant renal dysfunction (serum creatinine &gt;2.0 mg/dL),&#xD;
&#xD;
          -  Pregnant and breastfeeding women,&#xD;
&#xD;
          -  Hypersensitivity to apomorphine or any excipients of the medicinal product,&#xD;
&#xD;
          -  Concomitant therapy or within 28 days prior to baseline with : alpha-methyl dopa,&#xD;
             metoclopramide, reserpine, neuroleptics (except Clozapine), methylphenidate, or&#xD;
             amphetamine, intrajejunal Ldopa,&#xD;
&#xD;
          -  History or current drug or alcohol abuse or dependencies,&#xD;
&#xD;
          -  Patients with a borderline QT interval corrected for heart rate according to Bazett's&#xD;
             formula (QTc) of &gt;470 ms for male and &gt;480 ms for female at screening or history of&#xD;
             long QT syndrome;&#xD;
&#xD;
          -  Adults legally protected (under judicial protection, guardianship or supervision),&#xD;
             persons deprived of their liberty.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie DRAPIER, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie DRAPIER, Dr</last_name>
    <phone>+33 2 99 28 98 42</phone>
    <email>sophie.drapier@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amiens University Hospital</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa TIR, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bayonne Côte Basque Hospital</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie BANNIER, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pellegrin University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wassilios MEISSNER, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pierre Wertheimer Hospital</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chloé LAURENCIN, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles DEFER, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck DURIF, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lille University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc DEFEBVRE, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHM, hospital of Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre EUSEBIO, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Beau-Soleil</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie COCHEN DE COCK, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria GONZALEZ, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Régional de Mulhouse et Sud Alsace</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nancy University Hospital</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solène FRISMAND, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Laennec Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiphaine ROUAUD, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pasteur 2 University Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline GIORDANA, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caremeau University Hospital</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni CASTELNOVO, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtriere Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel FLAMAND ROZE, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Poitiers University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle BENATRU, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie DRAPIER, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Etienne University Hospital</name>
      <address>
        <city>Saint- Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domitille DILLY, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hautepierre University Hospital</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu ANHEIM, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Purpan University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine BREFEL-COURBON, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2016</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson disease</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Apomorphine infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apomorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

